Home / GIFLF : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does GIFLF make money? Does GIFLF have pricing power? What's the Earnings Whisper? Will GIFLF profit more as the business scales? What is GIFLF's management track record? Is GIFLF's current price justified?

Grifols, S.A.

$11.33 -$0.33 (-2.83%)

OTC · 11 Sep 2026 20:00 UTC

Previous Close

$11.33

Day Range

$10.45$11.33

Year Range

$10.13$13.9

Market Cap

7.71B

AVG Volume

373

Trailing/Forward PE

14.66/10.4

PEG ratio

0.49

Dividend Yield

0.84%

Next Earnings Date

2026-11-10

Primary Exchange

Other OTC

Revenue (EUR)

GIFLF Revenue (EUR) by year
Period	Revenue (EUR)
2025	7.52B
2024	7.21B
2023	6.57B
2022	6.06B
2021	4.93B
2020	5.34B
2019	5.1B
2018	4.49B
2017	4.32B
2016	4.05B

Net Income (EUR)

GIFLF Net Income (EUR) by year
Period	Net Income (EUR)
2025	401.86M
2024	156.92M
2023	164.97M
2022	208.28M
2021	188.73M
2020	708.99M
2019	625.14M
2018	596.64M
2017	662.7M
2016	545.46M

Operating Income (EUR)

GIFLF Operating Income (EUR) by year
Period	Operating Income (EUR)
2025	1.28B
2024	1.19B
2023	903.17M
2022	806.32M
2021	577.48M
2020	996.13M
2019	1.13B
2018	994.12M
2017	1B
2016	939.41M

EBITDA (EUR)

GIFLF EBITDA (EUR) by year
Period	EBITDA (EUR)
2025	1.48B
2024	1.53B
2023	1.41B
2022	1.04B
2021	815.6M
2020	1.39B
2019	1.45B
2018	1.2B
2017	1.16B
2016	1.12B

Cash Flows (EUR)

GIFLF Cash Flows (EUR) by year
Period	Cash Flows (EUR)
2025	781.87M
2024	606.63M
2023	-27.57M
2022	-266.24M
2021	320.5M
2020	747.78M
2019	156.63M
2018	429.71M
2017	518.77M
2016	260.59M

EPS (EUR)

GIFLF EPS (EUR) by year
Period	EPS (EUR)
2025	0.59
2024	0.22
2023	0.24
2022	0.3
2021	0.28
2020	1.04
2019	0.91
2018	0.87
2017	0.97
2016	0.8

Expenses (EUR)

GIFLF Expenses (EUR) by year
Period	Expenses (EUR)
2025	1.84B
2024	1.89B
2023	1.88B
2022	1.81B
2021	1.69B
2020	1.64B
2019	1.63B
2018	1.36B
2017	1.47B
2016	1.27B

Cash & Debt (EUR)

GIFLF Cash & Debt (EUR) by year
Period	Cash & Debt (EUR)
2025	848.18M
2024	1B
2023	544.5M
2022	578.61M
2021	2.68B
2020	590.51M
2019	2.47B
2018	1.03B
2017	886.52M
2016	895.01M

Debt ratios

GIFLF Debt ratios by year
Period	Debt ratios
2025	1.61
2024	1.89
2023	2.24
2022	1.95
2021	1.53
2020	1.22
2019	0.94
2018	1.14

Margins

GIFLF Margins by year
Period	Margins
2025	38.37%
2024	38.99%
2023	38.08%
2022	36.8%
2021	39.78%
2020	42.23%
2019	45.92%
2018	45.68%
2017	49.84%
2016	47.22%

Return on Capital

GIFLF Return on Capital by year
Period	Return on Capital
2025	5.29%
2024	1.82%
2023	2.07%
2022	2.46%
2021	2.58%
2020	10.55%
2019	9.13%
2018	12.7%
2017	18.24%
2016	14.63%

Shares Outstanding

GIFLF Shares Outstanding by year
Period	Shares Outstanding
2025	687.74M
2024	680.41M
2023	679.09M
2022	678.43M
2021	678.98M
2020	684.54M
2019	684.14M
2018	707.11M
2017	680.78M
2016	668.01M

Dividends (EUR)

GIFLF Dividends (EUR) by year
Period	Dividends (EUR)
2026	0.09
2025	0.18
2021	0.45
2020	0.19
2019	0.39
2018	0.47
2017	0.37
2016	0.34
2015	0.36
2014	0.29

Employee Count

GIFLF Employee Count by year
Period	Employee Count
2025	25.25K
2023	23.82K
2022	26.31K
2021	23.23K
2020	23.66K
2019	24K
2018	21.23K
2017	18.3K
2016	14.88K
2015	14.74K

Book Value Per Share (EUR)

GIFLF Book Value Per Share (EUR) by year
Period	Book Value Per Share (EUR)
2025	11.05
2024	12.65
2023	11.74
2022	12.47
2021	10.78
2020	9.82
2019	10.01
2018	6.64
2017	5.34
2016	5.58

Total Assets (EUR)

GIFLF Total Assets (EUR) by year
Period	Total Assets (EUR)
2025	19.7B
2024	21.41B
2023	21.45B
2022	21.53B
2021	19.23B
2020	15.27B
2019	15.54B
2018	12.48B
2017	10.92B
2016	10.13B

PE Ratio

GIFLF PE Ratio by year
Period	PE Ratio
Sep 26	14.69
Sep 26	14.35
Aug 26	15.27
Aug 26	15.15
Aug 26	15.29
Aug 26	15.3
Jul 26	13.37
Jul 26	14.76
Jul 26	14.68
Jul 26	14.85
Jul 26	15.03
Jun 26	15.71
Jun 26	15.6
Jun 26	15.68
Jun 26	16.51
May 26	16.32
May 26	16.4
May 26	15.55
May 26	15.35
May 26	15.43
Apr 26	15.43
Apr 26	15.37
Apr 26	15.42
Apr 26	19.12
Mar 26	19.18
Mar 26	19.08
Mar 26	19.3
Mar 26	19
Feb 26	18.67
Feb 26	18.07
Feb 26	17.93
Feb 26	18.01
Jan 26	17.96
Jan 26	17.99
Jan 26	18.35
Jan 26	18.29
Jan 26	18.16
Dec 25	18.08
Dec 25	18.18
Dec 25	18.13
Dec 25	18.28
Nov 25	18.35
Nov 25	18.49
Nov 25	21.83
Nov 25	21.94
Oct 25	27.79
Oct 25	27.66
Oct 25	27.61
Oct 25	27.67
Oct 25	27.39
Sep 25	27.5
Sep 25	27.4
Sep 25	27.43
Sep 25	27.45
Aug 25	27.53
Aug 25	27.44
Aug 25	27.48
Aug 25	27.64
Aug 25	27.77
Jul 25	41.26
Jul 25	41.97
Jul 25	34.14
Jul 25	33.94
Jun 25	34.06
Jun 25	37.19
Jun 25	33.03
Jun 25	33.49
May 25	32.08
May 25	32.03
May 25	26.53
May 25	32.76
May 25	32.61
Apr 25	32.42
Apr 25	32.41
Apr 25	32.42
Apr 25	37.69
Mar 25	53.73
Mar 25	53.84
Mar 25	53.47
Mar 25	53.76
Feb 25	56.13
Feb 25	46.31
Feb 25	46.18
Feb 25	43.16
Jan 25	43.04
Jan 25	44.21
Jan 25	47.93
Jan 25	48.04
Jan 25	47.74
Dec 24	44.78
Dec 24	44.76
Dec 24	44.44
Dec 24	42.32
Nov 24	51.06
Nov 24	50.42
Nov 24	52.81
Nov 24	51.8
Nov 24	49.82
Oct 24	50.74
Oct 24	50.42

Free Cash Flow Yield

GIFLF Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	11.54%
Sep 26	11.82%
Aug 26	11.1%
Aug 26	11.19%
Aug 26	11.08%
Aug 26	11.08%
Jul 26	12.67%
Jul 26	12.29%
Jul 26	12.36%
Jul 26	12.22%
Jul 26	12.08%
Jun 26	12.39%
Jun 26	12.47%
Jun 26	12.41%
Jun 26	11.78%
May 26	11.92%
May 26	11.86%
May 26	12.51%
May 26	12.68%
May 26	12.61%
Apr 26	12.61%
Apr 26	12.66%
Apr 26	12.62%
Apr 26	10.18%
Mar 26	10.15%
Mar 26	10.2%
Mar 26	10.08%
Mar 26	10.24%
Feb 26	10.42%
Feb 26	12.01%
Feb 26	12.1%
Feb 26	12.04%
Jan 26	12.08%
Jan 26	12.06%
Jan 26	11.82%
Jan 26	11.86%
Jan 26	11.95%
Dec 25	12%
Dec 25	11.93%
Dec 25	11.97%
Dec 25	11.87%
Nov 25	11.82%
Nov 25	11.73%
Nov 25	9.94%
Nov 25	9.89%
Oct 25	9.3%
Oct 25	9.34%
Oct 25	9.36%
Oct 25	9.34%
Oct 25	9.43%
Sep 25	9.4%
Sep 25	9.43%
Sep 25	9.42%
Sep 25	9.41%
Aug 25	9.39%
Aug 25	9.42%
Aug 25	9.4%
Aug 25	9.35%
Aug 25	9.3%
Jul 25	11.12%
Jul 25	10.93%
Jul 25	13.44%
Jul 25	13.52%
Jun 25	13.48%
Jun 25	12.34%
Jun 25	13.89%
Jun 25	13.7%
May 25	14.3%
May 25	14.33%
May 25	17.3%
May 25	11.8%
May 25	11.85%
Apr 25	11.93%
Apr 25	11.93%
Apr 25	11.92%
Apr 25	10.26%
Mar 25	3.72%
Mar 25	3.72%
Mar 25	3.74%
Mar 25	3.72%
Feb 25	3.56%
Feb 25	4.32%
Feb 25	4.33%
Feb 25	4.64%
Jan 25	4.65%
Jan 25	4.53%
Jan 25	4.18%
Jan 25	4.17%
Jan 25	4.19%
Dec 24	2.38%
Dec 24	2.39%
Dec 24	2.4%
Dec 24	2.52%
Nov 24	2.09%
Nov 24	2.12%
Nov 24	2.02%
Nov 24	2.06%
Nov 24	2.14%
Oct 24	2.1%
Oct 24	2.12%

Price to Sales

GIFLF Price to Sales by year
Period	Price to Sales
Sep 26	0.89
Sep 26	0.87
Aug 26	0.93
Aug 26	0.92
Aug 26	0.93
Aug 26	0.93
Jul 26	0.81
Jul 26	0.82
Jul 26	0.82
Jul 26	0.83
Jul 26	0.84
Jun 26	0.84
Jun 26	0.83
Jun 26	0.84
Jun 26	0.88
May 26	0.87
May 26	0.88
May 26	0.83
May 26	0.82
May 26	0.82
Apr 26	0.82
Apr 26	0.82
Apr 26	0.82
Apr 26	1.02
Mar 26	1.02
Mar 26	1.02
Mar 26	1.03
Mar 26	1.01
Feb 26	1
Feb 26	0.9
Feb 26	0.89
Feb 26	0.89
Jan 26	0.89
Jan 26	0.89
Jan 26	0.91
Jan 26	0.91
Jan 26	0.9
Dec 25	0.9
Dec 25	0.9
Dec 25	0.9
Dec 25	0.91
Nov 25	0.91
Nov 25	0.92
Nov 25	1.08
Nov 25	1.09
Oct 25	1.11
Oct 25	1.11
Oct 25	1.1
Oct 25	1.11
Oct 25	1.09
Sep 25	1.1
Sep 25	1.09
Sep 25	1.1
Sep 25	1.1
Aug 25	1.1
Aug 25	1.1
Aug 25	1.1
Aug 25	1.1
Aug 25	1.11
Jul 25	1.09
Jul 25	1.11
Jul 25	0.9
Jul 25	0.9
Jun 25	0.9
Jun 25	0.98
Jun 25	0.87
Jun 25	0.89
May 25	0.85
May 25	0.85
May 25	0.7
May 25	0.71
May 25	0.71
Apr 25	0.71
Apr 25	0.71
Apr 25	0.71
Apr 25	0.82
Mar 25	1.1
Mar 25	1.11
Mar 25	1.1
Mar 25	1.1
Feb 25	1.15
Feb 25	0.95
Feb 25	0.95
Feb 25	0.89
Jan 25	0.88
Jan 25	0.91
Jan 25	0.98
Jan 25	0.99
Jan 25	0.98
Dec 24	1
Dec 24	1
Dec 24	0.99
Dec 24	0.94
Nov 24	1.14
Nov 24	1.12
Nov 24	1.18
Nov 24	1.15
Nov 24	1.11
Oct 24	1.13
Oct 24	1.12

EV/EBITDA

GIFLF EV/EBITDA by year
Period	EV/EBITDA
Sep 26	9.05
Sep 26	8.95
Aug 26	9.21
Aug 26	9.17
Aug 26	9.21
Aug 26	9.22
Jul 26	8.68
Jul 26	10.54
Jul 26	10.52
Jul 26	10.57
Jul 26	10.62
Jun 26	10.2
Jun 26	10.17
Jun 26	10.19
Jun 26	10.42
May 26	10.37
May 26	10.39
May 26	10.16
May 26	10.1
May 26	10.13
Apr 26	10.13
Apr 26	10.11
Apr 26	10.12
Apr 26	11.13
Mar 26	11.14
Mar 26	11.12
Mar 26	11.18
Mar 26	11.09
Feb 26	11
Feb 26	4.52
Feb 26	4.49
Feb 26	4.51
Jan 26	4.49
Jan 26	4.5
Jan 26	4.59
Jan 26	4.57
Jan 26	4.54
Dec 25	4.52
Dec 25	4.55
Dec 25	4.53
Dec 25	4.57
Nov 25	4.59
Nov 25	4.62
Nov 25	5.43
Nov 25	5.45
Oct 25	10.61
Oct 25	10.59
Oct 25	10.58
Oct 25	10.59
Oct 25	10.54
Sep 25	10.56
Sep 25	10.54
Sep 25	10.54
Sep 25	10.55
Aug 25	10.56
Aug 25	10.54
Aug 25	10.55
Aug 25	10.58
Aug 25	10.61
Jul 25	10.79
Jul 25	10.88
Jul 25	9.91
Jul 25	9.89
Jun 25	9.9
Jun 25	10.29
Jun 25	9.78
Jun 25	9.83
May 25	9.66
May 25	9.65
May 25	8.97
May 25	9.32
May 25	9.3
Apr 25	9.28
Apr 25	9.28
Apr 25	9.28
Apr 25	9.82
Mar 25	9.59
Mar 25	9.59
Mar 25	9.56
Mar 25	9.59
Feb 25	9.78
Feb 25	8.97
Feb 25	8.96
Feb 25	8.72
Jan 25	8.71
Jan 25	8.8
Jan 25	9.11
Jan 25	9.12
Jan 25	9.09
Dec 24	9.3
Dec 24	9.3
Dec 24	9.27
Dec 24	9.07
Nov 24	9.88
Nov 24	9.82
Nov 24	10.04
Nov 24	9.95
Nov 24	9.77
Oct 24	9.85
Oct 24	9.82

Price/Operating Cashflow

GIFLF Price/Operating Cashflow by year
Period	Price/Operating Cashflow
Sep 26	6.08
Sep 26	5.93
Aug 26	6.32
Aug 26	6.27
Aug 26	6.33
Aug 26	6.33
Jul 26	5.53
Jul 26	6
Jul 26	5.97
Jul 26	6.04
Jul 26	6.11
Jun 26	6.03
Jun 26	5.99
Jun 26	6.02
Jun 26	6.34
May 26	6.27
May 26	6.3
May 26	5.97
May 26	5.89
May 26	5.92
Apr 26	5.92
Apr 26	5.9
Apr 26	5.92
Apr 26	7.34
Mar 26	7.36
Mar 26	7.32
Mar 26	7.41
Mar 26	7.29
Feb 26	7.17
Feb 26	5.95
Feb 26	5.91
Feb 26	5.94
Jan 26	5.92
Jan 26	5.93
Jan 26	6.05
Jan 26	6.03
Jan 26	5.99
Dec 25	5.96
Dec 25	5.99
Dec 25	5.98
Dec 25	6.03
Nov 25	6.05
Nov 25	6.09
Nov 25	7.2
Nov 25	7.23
Oct 25	7.48
Oct 25	7.45
Oct 25	7.43
Oct 25	7.45
Oct 25	7.37
Sep 25	7.4
Sep 25	7.38
Sep 25	7.38
Sep 25	7.39
Aug 25	7.41
Aug 25	7.39
Aug 25	7.4
Aug 25	7.44
Aug 25	7.48
Jul 25	6.7
Jul 25	6.81
Jul 25	5.54
Jul 25	5.51
Jun 25	5.53
Jun 25	6.04
Jun 25	5.36
Jun 25	5.44
May 25	5.21
May 25	5.2
May 25	4.31
May 25	5.7
May 25	5.67
Apr 25	5.64
Apr 25	5.64
Apr 25	5.64
Apr 25	6.56
Mar 25	14.22
Mar 25	14.25
Mar 25	14.15
Mar 25	14.23
Feb 25	14.85
Feb 25	12.25
Feb 25	12.22
Feb 25	11.42
Jan 25	11.39
Jan 25	11.7
Jan 25	12.68
Jan 25	12.71
Jan 25	12.63
Dec 24	17
Dec 24	16.99
Dec 24	16.87
Dec 24	16.06
Nov 24	19.38
Nov 24	19.14
Nov 24	20.04
Nov 24	19.66
Nov 24	18.91
Oct 24	19.26
Oct 24	19.13

Price to Book

GIFLF Price to Book by year
Period	Price to Book
Sep 26	0.83
Sep 26	0.81
Aug 26	0.87
Aug 26	0.86
Aug 26	0.87
Aug 26	0.87
Jul 26	0.76
Jul 26	0.78
Jul 26	0.77
Jul 26	0.78
Jul 26	0.79
Jun 26	0.83
Jun 26	0.82
Jun 26	0.83
Jun 26	0.87
May 26	0.86
May 26	0.87
May 26	0.82
May 26	0.81
May 26	0.82
Apr 26	0.82
Apr 26	0.81
Apr 26	0.82
Apr 26	1.01
Mar 26	1.01
Mar 26	1.01
Mar 26	1.02
Mar 26	1
Feb 26	0.99
Feb 26	0.89
Feb 26	0.89
Feb 26	0.89
Jan 26	0.89
Jan 26	0.89
Jan 26	0.91
Jan 26	0.9
Jan 26	0.9
Dec 25	0.89
Dec 25	0.9
Dec 25	0.9
Dec 25	0.9
Nov 25	0.91
Nov 25	0.91
Nov 25	1.08
Nov 25	1.08
Oct 25	1.09
Oct 25	1.08
Oct 25	1.08
Oct 25	1.08
Oct 25	1.07
Sep 25	1.08
Sep 25	1.07
Sep 25	1.07
Sep 25	1.07
Aug 25	1.08
Aug 25	1.07
Aug 25	1.08
Aug 25	1.08
Aug 25	1.09
Jul 25	0.97
Jul 25	0.99
Jul 25	0.8
Jul 25	0.8
Jun 25	0.8
Jun 25	0.88
Jun 25	0.78
Jun 25	0.79
May 25	0.76
May 25	0.75
May 25	0.62
May 25	0.6
May 25	0.59
Apr 25	0.59
Apr 25	0.59
Apr 25	0.59
Apr 25	0.69
Mar 25	0.97
Mar 25	0.97
Mar 25	0.96
Mar 25	0.97
Feb 25	1.01
Feb 25	0.83
Feb 25	0.83
Feb 25	0.78
Jan 25	0.77
Jan 25	0.8
Jan 25	0.86
Jan 25	0.86
Jan 25	0.86
Dec 24	0.82
Dec 24	0.82
Dec 24	0.81
Dec 24	0.77
Nov 24	0.93
Nov 24	0.92
Nov 24	0.97
Nov 24	0.95
Nov 24	0.91
Oct 24	0.93
Oct 24	0.92

No video analysis for this stock yet. Request one from our team.

News: GIFLF

seekingalpha.com · 15 Aug 2026

Oakmark International Small Cap Strategy Q2 2026 Portfolio Update

The portfolio's return was 5.34% (net) for the reporting period. We initiated the following positions: Birkenstock Holding, Dormakaba, Hiab, Reply, SATS Ltd., and Scout24. We eliminated the following positions: Grifols Cl B ADR and Sopra Steria Group.

seekingalpha.com · 3 Jul 2026

Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)

First-quarter results were broadly in line with expectations, supported by strong growth in the Biopharma division, particularly immunoglobulins, where products such as Gamunex and Yimmugo continue to outperform. Grifols successfully refinanced all 2027 debt maturities ahead of schedule, extending maturities, lowering funding costs, and reducing refinancing risk. Lower plasma collection costs (with the Egyptian plasma platform), optimization of the U.S. collection network, and continued Biotest integration are expected to support sustainable margin expansion.

globenewswire.com · 15 Jun 2026

Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.

BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency (CFD), including hypo- or afibrinogenemia, FESILTY™ (fibrinogen, human-chmt) is now available in the U.S. FESILTY is not indicated for dysfibrinogenemia.